Blood Cancer Clinical Trials 2024

Blood Cancer Clinical Trials 2024

Blood Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in blood cancer clinical trials today.

Blood Cancer Clinical Trials

Here are the 6 most popular medical studies for blood cancer

Popular filter options for blood cancer trials

Acute Myelogenous Leukemia Clinical Trials

View 22 Acute Myelogenous Leukemia medical studies.

Acute Lymphoblastic Leukemia Clinical Trials

View 21 Acute Lymphoblastic Leukemia medical studies.

Blood Cancer Clinical Trials With No Placebo

View 27 blood cancer medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to blood cancer

What are the top hospitals conducting blood cancer research?

When it comes to cutting-edge clinical trials in the field of blood cancer, several top hospitals have emerged as leaders. Memorial Sloan Kettering Cancer Center, located in New york City, is at the forefront with four ongoing blood cancer trials and an impressive track record of 35 completed studies since their first recorded trial in 2005. The National Institutes of Health Clinical Center in Bethesda also plays a significant role, conducting three active clinical trials focused on blood cancer and contributing to a total of 13 previous studies dating back to their inaugural trial in 2003.

In Boston, Massachusetts General Hospital has made notable contributions with three ongoing blood cancer trials and a history encompassing 19 prior investigations since initiating research on this condition back in 2002. Meanwhile, Tufts Medical Center boasts an equally commendable commitment with three current clinical tests for blood cancer and five previously conducted trials starting only recently in2011.

An additional institution making noteworthy strides is the City of Hope Medical Center situated in Duarte. Despite being smaller-scale by comparison when it comes to active trials or past endeavors both are dwarfed but its critical contribution lies within its three present-day investigations that hold promise for advancements against this complex disease; additionally adding value through eleven accomplished experiments from before whose humble origins date all the way back until1999.

These remarkable institutions across multiple locations serve as beacons of hope for those affected by various types of blood cancers. With each passing year and every new clinical trial conducted, researchers inch closer towards better understanding these diseases while developing innovative treatments that offer improved outcomes for patients around the world

Which are the best cities for blood cancer clinical trials?

When it comes to blood cancer clinical trials, several cities stand out as hotspots for research and development. Boston, Massachusetts leads the way with 9 active trials focusing on treatments like Enasidenib, BMS-986158, and TAK-981. New york, New York closely follows with 8 ongoing studies exploring therapies such as Enasidenib, CYNK-001, and Cord Blood Transplant. Duarte, California also joins the ranks with 8 active trials investigating treatment options like Enasidenib and AZD4573. Houston, Texas contributes to the field with 7 active trials studying interventions such as CYNK-001 and TAK-981. Finally, Bethesda in Maryland boasts 4 active trials examining treatments including Cyclophosphamide and Cord Blood Transplant. These cities offer individuals battling blood cancer access to cutting-edge clinical trials that have the potential to revolutionize care outcomes.

Which are the top treatments for blood cancer being explored in clinical trials?

The world of blood cancer research is abuzz with promising treatments currently being explored in clinical trials. Two top contenders include cyclophosphamide and cord blood transplant. Cyclophosphamide, first listed in 2000, has been involved in two active trials and an impressive 57 all-time blood cancer trials. Cord blood transplant, on the other hand, made its debut in 2012 and has since gained traction with two ongoing trials and one all-time trial dedicated to battling this complex disease. Another noteworthy treatment making waves is tranexamic acid—a newcomer that entered the scene in 2016—and has shown potential through one active trial and involvement in two previous studies focused on combating blood cancer. As researchers continue their efforts towards finding effective solutions for patients worldwide, these treatments offer glimpses of hope on the horizon.

What are the most recent clinical trials for blood cancer?

Exciting advancements are being made in the field of blood cancer research through recent clinical trials. One notable trial is exploring the potential of cord blood transplant as a treatment option for patients with blood cancer, showing promising results in phase 2. Another study focuses on dose escalation and matching techniques, aiming to optimize treatment outcomes for individuals with this challenging disease. Additionally, tranexamic acid has shown promise in phase 3 trials as a potential therapeutic intervention. Moreover, ongoing investigations into drugs like fedratinib and LOXO-338 hold great potential for improving patient care and survival rates in the future. These cutting-edge studies shed light on new pathways towards effective treatments against various types of blood cancers.

What blood cancer clinical trials were recently completed?

In recent years, multiple clinical trials have been completed for various blood cancers, showcasing the dedicated efforts of researchers in advancing treatment options. Notably, a trial sponsored by the National Cancer Institute (NCI) concluded in April 2021 and explored the potential of mRNA-1273 therapy. Similarly, Prelude Therapeutics conducted a trial on PRT1419 that ended in September 2020. Additionally, Epizyme's investigation into Tazemetostat was completed in April 2020. These studies contribute to our evolving understanding of blood cancer treatments and offer hope for patients grappling with these challenging diseases.